Allogene therapeutics, inc. (ALLO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-54,480

-61,030

-50,735

-41,243

-31,586

-30,509

-43,497

-134,902

-2,597

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation

14,215

13,874

12,835

11,487

7,867

5,871

4,639

8,056

0

Amortization of other intangible assets acquired

151

151

151

150

151

150

151

151

0

Depreciation and amortization

1,893

1,704

1,177

999

544

397

352

299

0

Net amortization/accretion on investment securities

207

460

851

1,062

1,223

1,161

-125

0

0

Non-cash rent expense

718

1,950

3,279

273

1,275

1,168

664

0

0

Benefit from income taxes

0

-

33

-159

-50

-

0

0

0

Share of losses from equity method investments

-64

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-2,552

5,531

-607

-1,371

1,892

5,466

2,795

342

-5

Other long-term assets

57

1,511

870

1,805

188

-1,224

1,468

0

0

Accounts payable

-1,044

2,152

-4,469

1,680

-348

5,717

1,815

1,268

0

Accrued and other current liabilities

-3,913

-1,159

7,617

3,988

-4,095

-557

111

9,987

2,597

Other long-term liabilities

-701

-434

-709

-571

-711

0

0

0

0

Net cash used in operating activities

-40,809

-50,267

-31,935

-24,892

-30,256

-21,481

-17,130

-6,047

5

Cash flows from investing activities:
Purchases of property and equipment

12,253

14,112

18,400

7,856

10,423

1,321

1,377

536

0

Proceeds from maturities of investments

120,261

116,813

158,350

101,707

95,708

19,235

0

0

0

Purchase of investments

123,015

89,697

61,175

49,359

52,397

333,908

315,399

0

0

Net cash (used in) provided by investing activities

-15,007

7,929

78,775

44,492

32,888

-313,388

-316,776

-2,634

0

Cash flows from financing activities:
Proceeds from issuance of common stock, net of commissions and issuance costs

14,845

-

-

-

0

-

-

-

-

Proceeds from issuance of common stock and upon exercise of stock options

303

2,255

467

236

0

-

-

-

-

Proceeds from issuance of common stock under the employee stock purchase plan

1,438

0

1,099

0

684

0

0

0

0

Net cash provided by financing activities

16,586

56,474

1,566

236

684

344,522

274,057

152,603

0

Net change in cash, cash equivalents and restricted cash

-39,230

14,136

48,406

19,836

3,316

9,653

-59,849

143,922

5

Non-cash investing activities:
Property and equipment purchases in accounts payable and accrued liabilities

4,208

-1,903

-7,096

8,533

5,134

2,978

144

60

0

Supplemental disclosure:
Cash paid for amounts included in the measurement of lease liabilities

1,396

1,381

1,026

765

391

31

0

0

0

Cash received for amounts related to tenant improvement allowances from lessors

532

-

-

-

0

-

-

-

-